Anti-inflammatory clearance of amyloid-β by a chimeric Gas6 fusion protein

Nat Med. 2022 Sep;28(9):1802-1812. doi: 10.1038/s41591-022-01926-9. Epub 2022 Aug 4.


Clearing amyloid-β (Aβ) through immunotherapy is one of the most promising therapeutic approaches to Alzheimer's disease (AD). Although several monoclonal antibodies against Aβ have been shown to substantially reduce Aβ burden in patients with AD, their effects on improving cognitive function remain marginal. In addition, a significant portion of patients treated with Aβ-targeting antibodies experience brain edema and microhemorrhage associated with antibody-mediated Fc receptor activation in the brain. Here, we develop a phagocytosis inducer for Aβ consisting of a single-chain variable fragment of an Aβ-targeting monoclonal antibody fused with a truncated receptor binding domain of growth arrest-specific 6 (Gas6), a bridging molecule for the clearance of dead cells via TAM (TYRO3, AXL, and MERTK) receptors. This chimeric fusion protein (αAβ-Gas6) selectively eliminates Aβ plaques through TAM receptor-dependent phagocytosis without inducing NF-kB-mediated inflammatory responses or reactive gliosis. Furthermore, αAβ-Gas6 can induce synergistic clearance of Aβ by activating both microglial and astrocytic phagocytosis, resulting in better behavioral outcomes with substantially reduced synapse elimination and microhemorrhage in AD and cerebral amyloid angiopathy model mice compared with Aβ antibody treatment. Our results suggest that αAβ-Gas6 could be a novel immunotherapeutic agent for AD that overcomes the side effects of conventional antibody therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Alzheimer Disease* / therapy
  • Amyloid beta-Peptides / metabolism
  • Animals
  • Anti-Inflammatory Agents / therapeutic use
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use
  • Disease Models, Animal
  • Mice
  • Mice, Transgenic
  • NF-kappa B
  • Plaque, Amyloid / drug therapy
  • Receptors, Fc / therapeutic use
  • Single-Chain Antibodies* / therapeutic use
  • c-Mer Tyrosine Kinase


  • Amyloid beta-Peptides
  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • NF-kappa B
  • Receptors, Fc
  • Single-Chain Antibodies
  • c-Mer Tyrosine Kinase